DSIP stands for delta sleep-inducing peptide. It is a nine-amino-acid neuropeptide (sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, molecular weight around 850 daltons) that the Schoenenberger-Monnier group in Switzerland isolated in 1974 from the cerebral venous blood of rabbits that had been put into a sleep-like state. The name describes what the original researchers saw in the rabbit EEG, not a proven therapy. Its INN is emideltide. You will also see it under the CAS number 62568-57-4.
The name oversells it. More than fifty years on, the peptide that DSIP comes from has not been pinned down in mammals, and its receptor and mechanism are still unsettled. A 2006 review in the Journal of Neurochemistry called DSIP "a still unresolved riddle," which is a fair summary of where the science sits.
What it is thought to do
DSIP is described as a neuromodulator rather than a straightforward sedative. Reported interactions include NMDA and GABA signaling, but no single receptor has been confirmed as its target. That ambiguity matters: in human and animal work the same compound has been reported to promote slow-wave (delta) sleep under some doses and timings, and to look mildly arousing under others. A direct sleeping-pill model does not fit the data.
Beyond sleep, the older literature attaches DSIP to stress-axis effects (lowering basal corticotropin, blunting stress-induced release) and various protective and regulatory roles. These come largely from animal and in vitro studies and should be read as proposed, not established.
The human evidence
There is some, and it is old and small. The most cited human study gave synthetic DSIP intravenously (25 nmol/kg) to six middle-aged chronic insomniacs and reported longer, less interrupted sleep with slightly more REM. The catch is in the timing: sleep promotion showed up only in the second hour after the injection, and the first hour carried a slight arousing effect (Schneider-Helmert, 1981). Separate clinical work in the 1980s explored DSIP for insomnia and other conditions with mixed results (A clinical trial with DSIP, 1984). Nothing since has built this into a consistent, replicated clinical picture.
So the honest read: a handful of small, decades-old human studies, no large modern trials, and contradictory findings on the very effect the peptide is named for.
Regulatory and quality status
DSIP is not an approved drug. It is not approved by the FDA, and it is not authorized as a medicine in the EU, Canada, or Australia. Material sold online is sold for research use only and is not intended for human consumption. Nothing here is medical or dosing advice.
For anyone evaluating a research-use vendor, the absence of regulatory oversight is exactly why third-party documentation matters. A certificate of analysis showing identity and purity (typically HPLC for purity, mass spec to confirm the correct nine-residue sequence) is the baseline. peptideone aggregates independent vendor ratings and testing signals so that paper trail, not marketing copy, is what you compare.